Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease
Public ClinicalTrials.gov record NCT04723537. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2/3 Study of Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A 2-part, multicenter, Phase 2/3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of upamostat in adult patients with COVID-19 disease who do not require inpatient care.
Study identification
- NCT ID
- NCT04723537
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Enrollment
- 61 participants
Conditions and interventions
Conditions
Interventions
- Part A: Upamostat 200 mg Drug
- Part A: Upamostat 400 mg Drug
- Part A and B: Placebo Drug
- Part B: Upamostat 200 or 400 mg Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 15, 2021
- Primary completion
- Dec 27, 2021
- Completion
- Dec 27, 2021
- Last update posted
- Jun 5, 2024
2021
United States locations
- U.S. sites
- 11
- U.S. states
- 6
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Beautiful Minds Clinical Research | Cutler Bay | Florida | 33157 | — |
| Research in Miami Inc. | Hialeah | Florida | 33013 | — |
| Angels Clinical Research Institute | Miami | Florida | 33122 | — |
| South Florida Research Phase I-IV, Inc. | Miami Springs | Florida | 33166 | — |
| Great Lakes Research Group | Bay City | Michigan | 48706 | — |
| Henry Ford Hospital, emergency department | Detroit | Michigan | 48202 | — |
| Prime Global Research | The Bronx | New York | 10456 | — |
| Montefiore Medical Center | The Bronx | New York | 10467 | — |
| On-Site Clinical Solutions | Charlotte | North Carolina | 28277 | — |
| University Hospitals Cleveland | Cleveland | Ohio | 44106 | — |
| Southwest Family Medicine Research | Dallas | Texas | 75235 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04723537, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 5, 2024 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04723537 live on ClinicalTrials.gov.